Get the Stockscreener App
104.67
0.14%
0.15
Pre-market:
105.30
0.63
+0.60%
Lantheus Holdings Inc stock is traded at $104.67, with a volume of 797.85K.
It is up +0.14% in the last 24 hours and up +11.46% over the past month.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
See More
Previous Close:
$104.52
Open:
$104.76
24h Volume:
797.85K
Relative Volume:
0.87
Market Cap:
$6.81B
Revenue:
$1.54B
Net Income/Loss:
$233.56M
P/E Ratio:
31.09
EPS:
3.3669
Net Cash Flow:
$348.64M
1W Performance:
+4.66%
1M Performance:
+11.46%
6M Performance:
+57.23%
1Y Performance:
+34.49%
1-Day Range:
$102.97
$104.99
1-Week Range:
$97.99
$104.99
52-Week Range:
$47.25
$104.99
Lantheus Holdings Inc Stock (LNTH) Company Profile
Name
Lantheus Holdings Inc
Sector
Phone
978 671-8001
Address
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Compare LNTH vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LNTH
Lantheus Holdings Inc
|
104.67 | 6.81B | 1.54B | 233.56M | 348.64M | 3.3669 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-12-25 | Upgrade | Truist | Hold → Buy |
| Oct-08-25 | Downgrade | Goldman | Buy → Neutral |
| Aug-12-25 | Downgrade | Truist | Buy → Hold |
| Dec-18-24 | Initiated | Goldman | Buy |
| Sep-03-24 | Initiated | Redburn Atlantic | Buy |
| Jul-10-24 | Reiterated | JMP Securities | Mkt Outperform |
| Dec-18-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-04-23 | Initiated | TD Cowen | Outperform |
| Sep-29-23 | Initiated | William Blair | Outperform |
| Mar-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Nov-30-22 | Initiated | SVB Leerink | Outperform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| May-09-22 | Initiated | B. Riley Securities | Buy |
| Apr-13-22 | Initiated | Truist | Buy |
| Feb-01-21 | Initiated | SVB Leerink | Outperform |
| Jun-29-20 | Resumed | Jefferies | Buy |
| Aug-16-19 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Nov-02-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-08-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-23-16 | Resumed | Credit Suisse | Neutral |
| Feb-24-16 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-11-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-30-15 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-20-15 | Initiated | Credit Suisse | Outperform |
| Jul-20-15 | Initiated | Jefferies | Buy |
| Jul-20-15 | Initiated | RBC Capital Mkts | Outperform |
| Jul-20-15 | Initiated | Robert W. Baird | Outperform |
| Jul-20-15 | Initiated | Wells Fargo | Outperform |
View All
Lantheus Holdings Inc Stock (LNTH) Latest News
LNTH Q1 2026 Earnings: EPS Surprises to the Upside on Solid Operational ExecutionSurprise Factor Analysis - newsline.com
Healthcare Stocks to Avoid: Lantheus, Merit Medical, Addus HomeCare AnalysisNews and Statistics - IndexBox
Lantheus Holdings stock hits 52-week high at 104.05 USD By Investing.com - Investing.com Nigeria
How SNMMI’s ‘Image of the Year’ Win For LNTH-2513 At Lantheus (LNTH) Has Changed Its Investment Story - Sahm
Lantheus Holdings stock hits 52-week high at 104.05 USD - Investing.com
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight - GlobeNewswire Inc.
Lantheus Holdings Inc stock (US5156731020): Expansion push and TruVu launch keep radiopharma story i - AD HOC NEWS
Lantheus Holdings gains after report it's evaluating a sale after offer - MSN
LNTH: TruVu launches regionally in late 2024, expanding PYLARIFY access and driving market growth - TradingView
Lantheus Holdings Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Lantheus Holdings, Inc. (LNTH): Analyst Consensus Highlights a Strong Buy with a 4.21% Upside Potential - DirectorsTalk Interviews
Cash from financing activities of Lantheus Holdings Inc – XETR:0L8 - TradingView
0L8 Stock Price and Chart — XETR:0L8 - TradingView
Lantheus Holdings Inc Statistics – XETR:0L8 - TradingView
ETFs Investing in Lantheus Holdings Inc Stocks - TradingView
Why Is LNTH Stock Up After Hours? - Stocktwits
Assessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price Gains - Yahoo Finance
Understanding Momentum Shifts in (LNTH) - Stock Traders Daily
Lantheus in the spotlight: Can pipeline offset pricing headwinds? By Investing.com - Investing.com Nigeria
William Blair Upgrades Lantheus(LNTH.US) to Buy Rating - Moomoo
Is Lantheus Holdings Inc (LNTH) Overvalued After 4.1% Rally? GF - GuruFocus
Lantheus (LNTH) director uses 381 shares for tax-withholding, retains over 27,000 - Stock Titan
Lantheus (LNTH) CEO Heino reports 1,227-share tax withholding and updated holdings - Stock Titan
Lantheus Holdings Jumps 5.0% Amid Sector-Wide Rally - AlphaStreet
LNTH: Isotope-driven innovation and robust supply chains fuel PET imaging growth and new product launches - TradingView
Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
FDA approves Lantheus’ PYLARIFY TruVu for prostate cancer imaging - Investing.com
Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year - The Manila Times
Lantheus Holdings, Inc. (LNTH) Investor Outlook: High Buy Ratings and Promising Growth Prospects - DirectorsTalk Interviews
LNTH Q1 2026 Earnings: EPS Surges Past Estimates, But Stock DeclinesRevenue Warning Signal - newsline.com
Lantheus Holdings (LNTH) price target increased by 10.39% to 103.33 - MSN
Lantheus Q1 2026 Earnings: EPS Beat of 15.85% Amid Flat Revenue DisclosureEPS Revision Trend - newsline.com
LNTH Stock Price, Quote & Chart | LANTHEUS HOLDINGS INC (NASDAQ:LNTH) - ChartMill
LNTH Maintains by Mizuho -- Price Target Raised to $115 - GuruFocus
Mizuho raises Lantheus stock price target to $115 amid sale talks - Investing.com UK
Mizuho Securities Maintains Lantheus(LNTH.US) With Buy Rating, Raises Target Price to $115 - Moomoo
Analysts Are Bullish on Top Healthcare Stocks: IQVIA Holdings (IQV), Lantheus (LNTH) - The Globe and Mail
Lantheus to present at William Blair Growth Stock Conference on June 3, highlighting its radiopharmaceutical advances. - Pluang
Lantheus to Present at the William Blair 46th Annual Growth Stock Conference - The Manila Times
Watch Lantheus' June 3 William Blair fireside chat online - Stock Titan
Mizuho raises Lantheus stock price target to $115 amid sale talks By Investing.com - Investing.com South Africa
Lantheus explores $7B sale: report - The Business Journals
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating - Moomoo
Lantheus Holdings (LNTH) Surges 9%: Key Levels and Momentum DriversHigh Dividend Factor - The Legal Advocate
Avoiding Lag: Real-Time Signals in (LNTH) Movement - Stock Traders Daily
Lantheus Holdings, Inc. (LNTH) Stock Analysis: A Healthcare Powerhouse With a 23.48% Return on Equity - DirectorsTalk Interviews
Lantheus Holdings Inc Stock (LNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):